A new study of adults with type 2 diabetes suggests more than 25 percent received intensive glucose-lowering therapy, including 18.7 percent who were at risk for treatment-related adverse effects because of advanced age and co-existing illnesses, according to a new study published online by JAMA Internal Medicine.
Clinical guidelines recommend a target hemoglobin A1c level less than 7.0 percent for most nonpregnant adults with type 2 diabetes. Patients with advanced age, a limited life expectancy and complex health problems likely will not benefit from tight glycemic control and could actually be harmed.
Rozalina G. McCoy, M.D., of Mayo Clinic, Rochester, Minn., and coauthors used an administrative claims data in their study of 31,542 adults to examine the association and frequency of intensive glucose-lowering treatment and severe hypoglycemia (abnormally low blood glucose) in adults with type 2 diabetes who were not using insulin.
In total, 8,048 (25.5 percent) patients were treated intensively, including 7,317 patients (26.5 percent) with low clinical complexity and 731 patients (18.7 percent) with high clinical complexity.
The intensive treatment of patients with high clinical complexity because of age (75 or older), other medical conditions, or both, increased the incidence of severe hypoglycemia from 1.7 percent to 3 percent, according to the results.
"Individualized assessment of clinical complexity, in addition to careful consideration of likely risks and benefits of intensive glucose-lowering therapy, is therefore an important part of patient-centered diabetes management," the authors conclude.
To read the full study, please visit the For The Media website.
(JAMA Intern Med. Published online June 6, 2016. doi:10.1001/jamainternmed.2016.2275. Available pre-embargo to the media at http://media.
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Media Advisory: To contact corresponding study author Rozalina G. McCoy, M.D., call Bob Nellis or Elizabeth Zimmerman Young at 507-284-5005 or email firstname.lastname@example.org.